LT2901341T - Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui - Google Patents
Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymuiInfo
- Publication number
- LT2901341T LT2901341T LTEP13840946.1T LT13840946T LT2901341T LT 2901341 T LT2901341 T LT 2901341T LT 13840946 T LT13840946 T LT 13840946T LT 2901341 T LT2901341 T LT 2901341T
- Authority
- LT
- Lithuania
- Prior art keywords
- cancers
- tumor
- identification
- treatment
- protective epitopes
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707295P | 2012-09-28 | 2012-09-28 | |
| PCT/US2013/062100 WO2014052707A2 (en) | 2012-09-28 | 2013-09-27 | Identification of tumor-protective epitopes for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2901341T true LT2901341T (lt) | 2019-09-25 |
Family
ID=50389139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13840946.1T LT2901341T (lt) | 2012-09-28 | 2013-09-27 | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10501801B2 (lt) |
| EP (1) | EP2901341B1 (lt) |
| JP (2) | JP6501708B2 (lt) |
| AU (2) | AU2013323368B2 (lt) |
| DK (1) | DK2901341T3 (lt) |
| ES (1) | ES2737757T3 (lt) |
| HR (1) | HRP20191182T1 (lt) |
| LT (1) | LT2901341T (lt) |
| WO (1) | WO2014052707A2 (lt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2901341T (lt) | 2012-09-28 | 2019-09-25 | The University Of Connecticut | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
| WO2015153991A1 (en) * | 2014-04-04 | 2015-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapy targeted to promote a systemic abscopal effect |
| JP2017528143A (ja) * | 2014-09-10 | 2017-09-28 | ザ ユニバーシティ オブ コネチカット | 癌の治療のための免疫防御ネオエピトープ同定 |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| EP3280738A4 (en) | 2015-04-08 | 2019-01-02 | Nantomics, LLC | Cancer neoepitopes |
| AU2016253145B2 (en) * | 2015-04-23 | 2020-07-02 | Nant Holdings Ip, Llc | Cancer neoepitopes |
| CA2984643A1 (en) | 2015-05-13 | 2016-11-17 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| KR20180026670A (ko) * | 2015-05-26 | 2018-03-13 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도 |
| WO2017011660A1 (en) * | 2015-07-14 | 2017-01-19 | Personal Genome Diagnostics, Inc. | Neoantigen analysis |
| JP2018525002A (ja) * | 2015-08-13 | 2018-09-06 | チャンピオンズ オンコロジー インコーポレイテッド | 疾患および障害の個別化された治療 |
| KR20180087246A (ko) | 2015-10-12 | 2018-08-01 | 난토믹스, 엘엘씨 | 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법 |
| US11626187B2 (en) | 2015-10-12 | 2023-04-11 | Nantomics Llc | Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors |
| JP6710004B2 (ja) * | 2016-03-15 | 2020-06-17 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| KR20190082850A (ko) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법 |
| EP3933408A1 (en) * | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| CA3096909A1 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2797868C (en) * | 2010-05-14 | 2023-06-20 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| AU2012261237B2 (en) * | 2011-05-24 | 2017-06-01 | BioNTech SE | Individualized vaccines for cancer |
| LT2901341T (lt) | 2012-09-28 | 2019-09-25 | The University Of Connecticut | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui |
-
2013
- 2013-09-27 LT LTEP13840946.1T patent/LT2901341T/lt unknown
- 2013-09-27 AU AU2013323368A patent/AU2013323368B2/en not_active Ceased
- 2013-09-27 JP JP2015534719A patent/JP6501708B2/ja not_active Expired - Fee Related
- 2013-09-27 EP EP13840946.1A patent/EP2901341B1/en not_active Not-in-force
- 2013-09-27 ES ES13840946T patent/ES2737757T3/es active Active
- 2013-09-27 US US14/431,093 patent/US10501801B2/en active Active
- 2013-09-27 WO PCT/US2013/062100 patent/WO2014052707A2/en active Application Filing
- 2013-09-27 DK DK13840946.1T patent/DK2901341T3/da active
-
2019
- 2019-01-10 JP JP2019002924A patent/JP2019058190A/ja active Pending
- 2019-06-20 AU AU2019204354A patent/AU2019204354A1/en not_active Abandoned
- 2019-07-01 HR HRP20191182TT patent/HRP20191182T1/hr unknown
- 2019-09-23 US US16/578,937 patent/US20200017922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013323368A1 (en) | 2015-04-09 |
| AU2013323368B2 (en) | 2019-03-21 |
| EP2901341A2 (en) | 2015-08-05 |
| WO2014052707A3 (en) | 2015-05-14 |
| EP2901341B1 (en) | 2019-04-10 |
| JP2015533082A (ja) | 2015-11-19 |
| JP2019058190A (ja) | 2019-04-18 |
| HRP20191182T1 (hr) | 2019-10-04 |
| US20150252427A1 (en) | 2015-09-10 |
| AU2019204354A1 (en) | 2019-07-11 |
| US10501801B2 (en) | 2019-12-10 |
| DK2901341T3 (da) | 2019-07-15 |
| WO2014052707A2 (en) | 2014-04-03 |
| US20200017922A1 (en) | 2020-01-16 |
| JP6501708B2 (ja) | 2019-04-17 |
| ES2737757T3 (es) | 2020-01-15 |
| EP2901341A4 (en) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| EP2901341A4 (en) | IDENTIFICATION OF TUMOR PROTECTIVE EPITOPES FOR THE TREATMENT OF CANCERS | |
| HK1213771A1 (zh) | 治療癌症的方法 | |
| IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
| HK1214128A1 (zh) | 癌症的治療 | |
| HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
| HK1205254A1 (en) | Methods of treatment of cancer | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1210023A1 (en) | Cancer treatment | |
| HK1204956A1 (en) | Treatment of cancer | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| EP2934500A4 (en) | COMBINATION THERAPY AGAINST CANCER | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| EP2849786A4 (en) | METHOD FOR THE TREATMENT OF GASCULAR CANCER | |
| ZA201504169B (en) | Anti-adam28 antibody for treating cancer | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| GB201222563D0 (en) | Cancer treatment | |
| GB201217890D0 (en) | Treatment of cancer | |
| IL239231A0 (en) | Combined cancer treatment | |
| HK1200094A1 (en) | Use of immunomodulators for the treatment of cancer | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201321531D0 (en) | Treatment for cancers | |
| GB201222950D0 (en) | Combination treatment of cancer |